<DOC>
	<DOCNO>NCT00316914</DOCNO>
	<brief_summary>RATIONALE : Calcium gluconate magnesium sulfate may prevent lessen neurotoxicity cause oxaliplatin . It yet know whether calcium gluconate magnesium sulfate effective placebo prevent neurotoxicity cause oxaliplatin patient receive combination chemotherapy . PURPOSE : This randomized phase III trial study calcium gluconate magnesium sulfate see well work compare placebo prevent neurotoxicity cause oxaliplatin patient receive combination chemotherapy stage II , stage III , stage IV colorectal cancer completely remove surgery .</brief_summary>
	<brief_title>Calcium Gluconate Magnesium Sulfate Preventing Neurotoxicity Caused By Oxaliplatin Patients Receiving Combination Chemotherapy Stage II , Stage III , Stage IV Colorectal Cancer That Has Been Completely Removed By Surgery</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether calcium gluconate magnesium sulfate ( CaMg ) infusion prevent ameliorate chronic , cumulative oxaliplatin-induced neurotoxicity patient receive FOLFOX combination chemotherapy stage II , III IV colorectal cancer . - Determine whether CaMg infusion increase cumulative oxaliplatin dos deliver without chronic neurotoxicity . - Determine whether CaMg infusion ameliorate acute neuropathy associate oxaliplatin . - Determine whether CaMg infusion cause adverse event . - Investigate whether CaMg infusion influence quality life , fatigue , activity daily live patient . - Determine polymorphism GSTP1 gene predict early onset oxaliplatin-induced neurotoxicity . OUTLINE : This randomize , placebo-controlled , double-blind , multicenter study . Patients stratify accord age ( &lt; 65 v &gt; 65 ) , gender , chemotherapy regimen ( FOLFOX4 vs modify FOLFOX6 ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive calcium gluconate magnesium sulfate IV 30 minute immediately oxaliplatin administration ( every 2 week ) assign chemotherapy regimen . - Arm II : Patients receive placebo IV 30 minute immediately oxaliplatin administration ( every 2 week ) assign chemotherapy regimen . In arm , treatment continue chemotherapy discontinue ( approximately 6 month ) . Patients complete quality life questionnaire day 1 , symptom experience diary day 2-5 chemotherapy regimen , questionnaires 1 3 month completion study treatment . Blood sample collect baseline test GSTP1 gene . After completion study treatment , patient follow least 3 month . PROJECTED ACCRUAL : A total 300 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Magnesium Sulfate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm adenocarcinoma colon rectum Stage II disease Stage III disease Stage IV disease ( completely resect evidence residual tumor ) Must undergone curative resection stage II III disease Scheduled receive 6 month adjuvant treatment either follow FOLFOX chemotherapy regimen : FOLFOX4 , comprise leucovorin calcium , fluorouracil , oxaliplatin ( 2week course ) Modified FOLFOX6 , comprise highdose leucovorin calcium , highdose fluorouracil , oxaliplatin ( 2week course ) PATIENT CHARACTERISTICS : Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10 g/dL WBC ≥ 3,000/mm^3 Bilirubin ≤ 1.5 time upper limit normal ( ULN ) Creatinine ≤ 1.5 time ULN Calcium normal Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No preexist peripheral neuropathy grade No hypercalcemia No concurrent heart block history heart block No medical condition , opinion treat physician , would make protocol unreasonably hazardous patient No family history genetic/familial neuropathy PRIOR CONCURRENT THERAPY : See Disease Characteristics No prior treatment neurotoxic chemotherapy oxaliplatin , cisplatin , taxanes , vinca alkaloid Concurrent use bevacizumab cetuximab combination FOLFOX part clinical trial clinical practice allow No concurrent digitalis medication No concurrent digoxin No concurrent treatment anticonvulsant carbamazepine , phenytoin , valproic acid No concurrent neurotropic agent gabapentin</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>neurotoxicity</keyword>
	<keyword>stage II colon cancer</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>stage II rectal cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>